foscarbidopa/foslevodopa; levodopa/carbidopa phosphate (ABBV-951)
Jump to navigation
Jump to search
Indications
- continuous subcutaneous drug treatment for Parkinson's disease (investigational)
Dosage
- delivered subcutaneously via a continuous-delivery infusion pump
Adverse effects
- infusion-site erythema (27%)
- pain (26%)
- cellulitis (19%); catheter-site & infusion-site cellulitis uncommon [[2]
- edema (12%)[2]
Clinical significance
- may increase "on" time without increasing dyskinesia[2]
More general terms
Components
References
- ↑ Rosebraugh M et al. Foslevodopa/foscarbidopa: A new subcutaneous treatment for Parkinson's disease. Ann Neurol 2021 Mar 26; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33772855 https://onlinelibrary.wiley.com/doi/10.1002/ana.26073
- ↑ 2.0 2.1 2.2 Soileau MJ et al. Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: A randomised, double-blind, active-controlled, phase 3 trial. Lancet Neurol 2022 Dec; 21:1099 PMID: https://www.ncbi.nlm.nih.gov/pubmed/36402160 https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(22)00400-8/fulltext